ALIGOS Therapeutics

  • About
    • Overview
    • Management
    • Board of Directors
  • Science
    • Pipeline
    • Posters & Presentations
  • Patients
    • Chronic HBV Infection
    • Clinical Trials
    • Expanded Access Policy
  • News & Media
    • Press Releases
    • Presentations & Events
  • Investors
    • Overview
    • Stock
      • Stock Quote & Chart
      • Analyst Coverage
    • News & Events
      • News Releases
      • Investor Calendar
    • Financials
      • SEC Filings
      • Quarterly Results
    • Governance
      • Governance Highlights
      • Committee Composition
    • Resources
      • Investor FAQs
      • Email Alerts
      • Contact IR
  • Careers
  • About
    • Overview
    • Management
    • Board of Directors
  • Science
    • Pipeline
    • Posters & Presentations
  • Patients
    • Chronic HBV Infection
    • Clinical Trials
    • Expanded Access Policy
  • News & Media
    • Press Releases
    • Presentations & Events
  • Investors
    • Overview
    • Stock
      • Stock Quote & Chart
      • Analyst Coverage
    • News & Events
      • News Releases
      • Investor Calendar
    • Financials
      • SEC Filings
      • Quarterly Results
    • Governance
      • Governance Highlights
      • Committee Composition
    • Resources
      • Investor FAQs
      • Email Alerts
      • Contact IR
  • Careers

Hepatocellular carcinoma, Selective inhibition of human β-catenin DNA transactivation activity using splice switching oligonucleotides for an improved therapeutic window in treating hepatocellular carcinoma

Preclinical, Publications

Hepatocellular carcinoma, Selective inhibition of human β-catenin DNA transactivation activity using splice switching oligonucleotides for an improved therapeutic window in treating hepatocellular carcinoma

Preclinical, Publications

Discovery of a Liver-Targeted PD-L1 Small Molecule Inhibitor for the Treatment of Chronic Hepatitis B and Liver Cancer

Preclinical, Publications

Discovery of Liver-targeted Oral PD-L1 Small Molecule Inhibitors for the Treatment of Chronic Hepatitis B and Liver Cancers

Preclinical, Publications

HAP Class I Capsid Assembly Modulators Clear Hepatitis B Virus-Infected Hepatocytes Through Core-dependent Hepatocyte Death and Subsequent Proliferation

Preclinical, Publications

Non-HAP class I capsid assembly modulators have distinct profiles and a differentiated mechanism of action

Preclinical, Publications

Suppression of PD-L1 expression by a novel liver-targeted siRNA leads to potential restoration of immune responses against HBV

Preclinical, Publications

Discovery of Highly Potent Oligonucleotides Targeting SARS-CoV-2

Preclinical, Publications

SARS-CoV-2 Viruses with Cross-Resistance to 3CLpro Inhibitors can be Selected In Vitro, and can Replicate and Transmit in a Hamster Model

Preclinical, Publications

Discovery of oral PD-L1 small molecule inhibitors specifically designed for the treatment of chronic hepatitis B

Preclinical, Publications

ALG-005398 is a Potent Non-HAP Class I HBV Capsid Assembly Modulator that Strongly Reduces HBsAg Levels In Vivo

US OFFICE
1 Corporate Dr., 2nd Floor
South San Francisco, CA 94080

EU OFFICE
Gaston Geenslaan 1 / (Building 3)
3001 Leuven, Belgium
+32 (0)16 88 28 10

CHINA OFFICE
Unit 3212, Building A, No. 100, Zunyi Road, Changning District, Shanghai, People’s Republic of China, 200051

FOLLOW US

info@aligos.com

© Aligos Therapeutics 2026

  • Privacy Policy
  • Terms of Service
  • Financial Conflict of Interest Policy
  • Research Integrity Policy
MENU
  • About
    • Overview
    • Management
    • Board of Directors
  • Science
    • Pipeline
    • Posters & Presentations
  • Patients
    • Chronic HBV Infection
    • Clinical Trials
    • Expanded Access Policy
  • News & Media
    • Press Releases
    • Presentations & Events
  • Investors
    • Overview
    • Stock
      • Stock Quote & Chart
      • Analyst Coverage
    • News & Events
      • News Releases
      • Investor Calendar
    • Financials
      • SEC Filings
      • Quarterly Results
    • Governance
      • Governance Highlights
      • Committee Composition
    • Resources
      • Investor FAQs
      • Email Alerts
      • Contact IR
  • Careers